These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21881837)

  • 1. Brain tissue echogenicity--implications for substantia nigra studies in parkinsonian patients.
    Sadowski K; Szlachta K; Serafin-Król M; Gałązka-Friedman J; Friedman A
    J Neural Transm (Vienna); 2012 Mar; 119(3):363-7. PubMed ID: 21881837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantia nigra echogenicity is associated with serum ferritin, gender and iron-related genes in Parkinson's disease.
    Li K; Ge YL; Gu CC; Zhang JR; Jin H; Li J; Cheng XY; Yang YP; Wang F; Zhang YC; Chen J; Mao CJ; Liu CF
    Sci Rep; 2020 May; 10(1):8660. PubMed ID: 32457446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial sonography in Parkinson's disease.
    Bor-Seng-Shu E; Pedroso JL; Andrade DC; Barsottini OG; Andrade LA; Barbosa ER; Teixeira MJ
    Einstein (Sao Paulo); 2012; 10(2):242-6. PubMed ID: 23052464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microglia activation is related to substantia nigra echogenicity.
    Berg D; Godau J; Riederer P; Gerlach M; Arzberger T
    J Neural Transm (Vienna); 2010 Nov; 117(11):1287-92. PubMed ID: 21057966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.
    Berg D
    J Neural Transm (Vienna); 2006 Jun; 113(6):775-80. PubMed ID: 16755382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography.
    Becker G; Seufert J; Bogdahn U; Reichmann H; Reiners K
    Neurology; 1995 Jan; 45(1):182-4. PubMed ID: 7824114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder.
    Iranzo A; Stockner H; Serradell M; Seppi K; Valldeoriola F; Frauscher B; Molinuevo JL; Vilaseca I; Mitterling T; Gaig C; Vilas D; Santamaria J; Högl B; Tolosa E; Poewe W
    Mov Disord; 2014 Dec; 29(14):1774-80. PubMed ID: 25384461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. a preliminary observation.
    Pedroso JL; Bor-Seng-Shu E; Felicio AC; Braga-Neto P; Dutra LA; de Aquino CC; Ferraz HB; do Prado GF; Teixeira MJ; Barsottini OG
    J Neurol Sci; 2012 Aug; 319(1-2):59-62. PubMed ID: 22632781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome.
    Schmidauer C; Sojer M; Seppi K; Stockner H; Högl B; Biedermann B; Brandauer E; Peralta CM; Wenning GK; Poewe W
    Ann Neurol; 2005 Oct; 58(4):630-4. PubMed ID: 16037973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.
    Berg D; Roggendorf W; Schröder U; Klein R; Tatschner T; Benz P; Tucha O; Preier M; Lange KW; Reiners K; Gerlach M; Becker G
    Arch Neurol; 2002 Jun; 59(6):999-1005. PubMed ID: 12056937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperechogenicity of the substantia nigra in Parkinson's disease.
    Ressner P; Skoloudík D; Hlustík P; Kanovský P
    J Neuroimaging; 2007 Apr; 17(2):164-7. PubMed ID: 17441838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT].
    Hernández Vara J; Rubiera del Fueyo M; Lorenzo Bosquet C; Castell Conesa J; Molina Cateriano CA; Rodríguez FM
    Med Clin (Barc); 2008 Sep; 131(8):285-9. PubMed ID: 18803921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease.
    Ruprecht-Dörfler P; Berg D; Tucha O; Benz P; Meier-Meitinger M; Alders GL; Lange KW; Becker G
    Neuroimage; 2003 Feb; 18(2):416-22. PubMed ID: 12595195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease.
    Iova A; Garmashov A; Androuchtchenko N; Kehrer M; Berg D; Becker G; Garmashov Y
    J Neurol; 2004 Dec; 251(12):1451-4. PubMed ID: 15645343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron accumulation in the substantia nigra in rats visualized by ultrasound.
    Berg D; Grote C; Rausch WD; Mäurer M; Wesemann W; Riederer P; Becker G
    Ultrasound Med Biol; 1999 Jul; 25(6):901-4. PubMed ID: 10461717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of substantia nigra echogenicity in German and Filipino populations using a portable ultrasound system.
    Go CL; Frenzel A; Rosales RL; Lee LV; Benecke R; Dressler D; Walter U
    J Ultrasound Med; 2012 Feb; 31(2):191-6. PubMed ID: 22298861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantia nigra hyperechogenicity in Parkinson's disease.
    Bor-Seng-Shu E; Fonoff ET; Barbosa ER; Teixeira MJ
    Acta Neurochir (Wien); 2010 Dec; 152(12):2085-7. PubMed ID: 20623147
    [No Abstract]   [Full Text] [Related]  

  • 19. Substantia nigra echogenicity correlated with clinical features of Parkinson's disease.
    Zhou HY; Sun Q; Tan YY; Hu YY; Zhan WW; Li DH; Wang Y; Xiao Q; Liu J; Chen SD
    Parkinsonism Relat Disord; 2016 Mar; 24():28-33. PubMed ID: 26842545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantia nigra echogenicity in Parkinson's disease: relation to serum iron and C-reactive protein.
    Walter U; Witt R; Wolters A; Wittstock M; Benecke R
    J Neural Transm (Vienna); 2012 Jan; 119(1):53-7. PubMed ID: 21626410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.